Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04166565
Title Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease (EMN19)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors European Myeloma Network
Age Groups: adult | senior
Covered Countries ITA

No variant requirements are available.